Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900019 | 0.90 | ALOX15 (0.39) | KDM4EALDH1A1RXFP1L3MBTL1HSD17B10 | |
| SCHEMBL4932447 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL14088339 | 0.78 | MAPK1 (0.52) | KDM4EALDH1A1KMT2AMEN1PDE4B | |
| SCHEMBL4575033 | 0.78 | ALDH1A1 (0.36) | KDM4EALDH1A1LMNA | |
| SCHEMBL14006502 | 0.78 | ALDH1A1 (0.37) | KDM4EALDH1A1KMT2APDE4BLMNA | |
| SCHEMBL14006442 | 0.78 | ALDH1A1 (0.35) | KDM4EALDH1A1LMNA | |
| SCHEMBL4909426 | 0.76 | ALDH1A1 (0.40) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL14006537 | 0.72 | ALDH1A1 (0.39) | KDM4EALDH1A1L3MBTL1PDE4BLMNA | |
| SCHEMBL335086 | 0.72 | ALDH1A1 (0.46) | KDM4EALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL3848263 | 0.67 | LMNA (0.38) | KDM4EALDH1A1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188466-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188466-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188466-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188466-A1 | PYRIDAZINONE COMPOUNDS | HAVCR2, PLPBP, CYP3A43 | KDM4E 3033/4885ALDH1A1 1191/4885KMT2A 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.